NCT02132832View on ClinicalTrials.gov

Buspirone, Stress, and Attentional Bias to Marijuana Cues

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Cannabis Use Disorder
Interventions
DRUG

Buspirone

Buspirone is an anxiolytic compound marked by modulation of both 5-HT1A and D3 receptors. Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.

DRUG

Placebo

Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.

Trial Locations (1)

77030

University of Texas Health Science Center - Houston, Houston

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

The University of Texas Health Science Center, Houston

OTHER

NCT02132832 - Buspirone, Stress, and Attentional Bias to Marijuana Cues | Biotech Hunter | Biotech Hunter